Analysis of Immune-Related Adverse Reactions in Patients with Classical Hodgkin Lymphoma (cHL) on Programmed Death-1 (PD-1) Inhibitor Therapy

MLA

Michael Brave, et al. “Analysis of Immune-Related Adverse Reactions in Patients with Classical Hodgkin Lymphoma (CHL) on Programmed Death-1 (PD-1) Inhibitor Therapy.” Blood, vol. 132, Nov. 2018, p. 1652. EBSCOhost, https://doi.org/10.1182/blood-2018-99-114101.

APA

Michael Brave, Barry W. Miller, Gideon M. Blumenthal, Jinzhong Liu, & Donna Przepiorka. (2018). Analysis of Immune-Related Adverse Reactions in Patients with Classical Hodgkin Lymphoma (cHL) on Programmed Death-1 (PD-1) Inhibitor Therapy. Blood, 132, 1652. https://doi.org/10.1182/blood-2018-99-114101

Chicago

Michael Brave, Barry W. Miller, Gideon M. Blumenthal, Jinzhong Liu, and Donna Przepiorka. 2018. “Analysis of Immune-Related Adverse Reactions in Patients with Classical Hodgkin Lymphoma (CHL) on Programmed Death-1 (PD-1) Inhibitor Therapy.” Blood 132 (November): 1652. doi:10.1182/blood-2018-99-114101.